drugset
drugset / Trial / NCT04571515

Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain

NCT04571515 ↗

Phase 2 Completed 114 enrolled Mylan Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

MR-107A-01 is being studied to investigate its efficacy, safety, and dose-response after dental surgery.

Timeline

Start
2020-09-29
Primary completion
2020-12-15
Completion
2020-12-22

Outcome

Met primary endpoint

registry analysis (superiority test); MR-107A-01 10 mg Once in a 24-hour Period vs Placebo Twice in a 24-hour Period; p = 0.003 NCT04571515 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject MR-107A-01 Unknown 10 mg Oral
Subject MR-107A-01 Unknown 15 mg Oral

Indications

No indication recorded.